Position of the Transparency Council – Enspryng (satralizumab)

At its meeting on 30 September 2024, the Transparency Council adopted position No. 100/2024 on the evaluation of the drug Enspryng (satralizumab) within the framework of the drug program “Treatment of patients with neuritis and myelitis spectrum disorder (NMOSD) (ICD-10: G36.0)”

Publication of the position >>